# Efficacy and Safety of Camrelizumab in Real-World Prospective Study

> **NCT04793139** · — · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 1000 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04793139
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2021-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04793139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04793139, "Efficacy and Safety of Camrelizumab in Real-World Prospective Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04793139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*